Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Obesity Study).
Blood pressure
HbA1c
Lipid metabolism
Obesity
Type 2 diabetes
Journal
Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
10
2018
accepted:
05
01
2019
pubmed:
21
3
2019
medline:
11
2
2020
entrez:
21
3
2019
Statut:
ppublish
Résumé
Obesity is the main obstacle for metabolic control in patients with type 2 diabetes. Turkey has the highest prevalence of obesity and type 2 diabetes in Europe. The effect of obesity on the metabolic control, and the macro- and microvascular complications of patients are not apparent. This nationwide survey aimed to investigate the prevalence of overweight and obesity among patients with type 2 diabetes and to search for the impact of obesity on the metabolic control of these patients. We also investigated the independent associates of obesity in patients with type 2 diabetes. We consecutively enrolled patients who were under follow-up for at least 1 year in 69 tertiary healthcare units in 37 cities. The demographic, anthropometric, and clinical data including medications were recorded. Patients were excluded if they were pregnant, younger than 18 years, had decompensated liver disease, psychiatric disorders interfering with cognition or compliance, had bariatric surgery, or were undergoing renal replacement therapy. Only 10% of patients with type 2 diabetes (n = 4,648) had normal body mass indexes (BMI), while the others were affected by overweight (31%) or obesity (59%). Women had a significantly higher prevalence of obesity (53.4 vs. 40%) and severe obesity (16.6 vs. 3.3%). Significant associations were present between high BMI levels and lower education levels, intake of insulin, antihypertensives and statins, poor metabolic control, or the presence of microvascular complications. Age, gender, level of education, smoking, and physical inactivity were the independent associates of obesity in patients with type 2 diabetes. The TEMD Obesity Study shows that obesity is a major determinant of the poor metabolic control in patients with type 2 diabetes. These results underline the importance of prevention and management of obesity to improve health care in patients with type 2 diabetes. Also, the results point out the independent sociodemographic and clinical associates of obesity, which should be the prior targets to overcome, in the national fight with obesity.
Sections du résumé
BACKGROUND
Obesity is the main obstacle for metabolic control in patients with type 2 diabetes. Turkey has the highest prevalence of obesity and type 2 diabetes in Europe. The effect of obesity on the metabolic control, and the macro- and microvascular complications of patients are not apparent.
OBJECTIVES
This nationwide survey aimed to investigate the prevalence of overweight and obesity among patients with type 2 diabetes and to search for the impact of obesity on the metabolic control of these patients. We also investigated the independent associates of obesity in patients with type 2 diabetes.
METHODS
We consecutively enrolled patients who were under follow-up for at least 1 year in 69 tertiary healthcare units in 37 cities. The demographic, anthropometric, and clinical data including medications were recorded. Patients were excluded if they were pregnant, younger than 18 years, had decompensated liver disease, psychiatric disorders interfering with cognition or compliance, had bariatric surgery, or were undergoing renal replacement therapy.
RESULTS
Only 10% of patients with type 2 diabetes (n = 4,648) had normal body mass indexes (BMI), while the others were affected by overweight (31%) or obesity (59%). Women had a significantly higher prevalence of obesity (53.4 vs. 40%) and severe obesity (16.6 vs. 3.3%). Significant associations were present between high BMI levels and lower education levels, intake of insulin, antihypertensives and statins, poor metabolic control, or the presence of microvascular complications. Age, gender, level of education, smoking, and physical inactivity were the independent associates of obesity in patients with type 2 diabetes.
CONCLUSION
The TEMD Obesity Study shows that obesity is a major determinant of the poor metabolic control in patients with type 2 diabetes. These results underline the importance of prevention and management of obesity to improve health care in patients with type 2 diabetes. Also, the results point out the independent sociodemographic and clinical associates of obesity, which should be the prior targets to overcome, in the national fight with obesity.
Identifiants
pubmed: 30893706
pii: 000496624
doi: 10.1159/000496624
pmc: PMC6547285
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-178Informations de copyright
© 2019 The Author(s) Published by S. Karger AG, Basel.
Références
Expert Opin Pharmacother. 2018 Jul;19(10):1087-1095
pubmed: 29958007
BMJ Open. 2016 Nov 3;6(11):e012742
pubmed: 27810975
Diabetes Res Clin Pract. 2018 Dec;146:138-147
pubmed: 30244051
J Clin Endocrinol Metab. 2015 Feb;100(2):363-70
pubmed: 25590213
Endocr J. 2018 May 28;65(5):527-536
pubmed: 29526989
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
Obesity (Silver Spring). 2010 May;18(5):1046-54
pubmed: 19875998
BMC Public Health. 2015 Dec 14;15:1238
pubmed: 26666320
PLoS Med. 2012;9(6):e1001230
pubmed: 22679397
Curr Med Res Opin. 2015;31(9):1623-31
pubmed: 26051230
BMJ. 1989 Dec 16;299(6714):1497-502
pubmed: 2514861
Curr Med Res Opin. 2005 Nov;21(11):1755-61
pubmed: 16307695
Scand J Public Health. 2008 Jun;36(4):397-407
pubmed: 18539694
Am J Cardiol. 2010 Nov 1;106(9):1270-6
pubmed: 21029823
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Diabetes Care. 2008 Jul;31(7):1367-72
pubmed: 18375414
N Engl J Med. 1987 Nov 19;317(21):1303-9
pubmed: 3683458
Nutrients. 2013 Apr 12;5(4):1218-40
pubmed: 23584084
PLoS One. 2013;8(3):e59153
pubmed: 23536864
N Engl J Med. 1991 Mar 14;324(11):739-45
pubmed: 1997840
Arch Intern Med. 2002 Sep 9;162(16):1867-72
pubmed: 12196085
Int J Obes. 1984;8(4):365-75
pubmed: 6511171
N Engl J Med. ;377(15):1495
pubmed: 29022333
Diabetes Care. 2018 Jan;41(Suppl 1):S1-S2
pubmed: 29222369
Eur J Epidemiol. 2013 Feb;28(2):169-80
pubmed: 23407904
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
J Am Coll Cardiol. 2013 Apr 16;61(15):1607-15
pubmed: 23500281
Cardiovasc Diabetol. 2016 Feb 10;15:29
pubmed: 26864124
Postgrad Med J. 2006 Apr;82(966):280-4
pubmed: 16597817
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Ann N Y Acad Sci. 2013 Apr;1281:64-91
pubmed: 23551121
JAMA. 2007 Dec 12;298(22):2654-64
pubmed: 18073361
Diabetes Metab Syndr. 2017 Jan - Mar;11(1):73-79
pubmed: 27353549
Can J Diabetes. 2015 Dec;39 Suppl 5:S148-54
pubmed: 26654858